Drugs / AB-110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03483324 | Apr 2018 → Dec 2020 | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Angiocrine Bioscience | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03483324 ↗ |
| Modality | Cell therapy | “Expanded cord blood stem cells and engineered human endothelial cells” NCT03483324 ↗ |